About

Nicholas Vardy is the editor of Bull Market Alert, The Alpha Algorithm, The Alpha Investor Letter, and The Global Guru, published by Eagle Financial Publications. Mr. Vardy is a regular contributor to Dow Jones Dow Jones Marketwatch and has been quoted in the Financial Times, Investor's Business Daily, MSN Money Central, AOL, and Yahoo Finance. He has also appeared on the Fox Business Network and CNN International. Mr. Vardy is a graduate of Stanford University and Harvard Law School, as well as a former Fulbright Scholar.




Content from Nicholas Vardy

Wilbur Ross’ Contrarian Bet on Shipping
Nicholas Vardy

Wilbur Ross — a long-time friend of President Trump and now U.S. Commerce Secretary — is one of Wall Street's leadi...

Tickers: NVGS
A Dozen Reasons to Buy Johnson & Johnson
Nicholas Vardy

For our latest recommendation, we are revisting a previous pick with big momentum - Johnson & Johnson (JNJ), which is currently...

Tickers: JNJ
Facebook Gets a "Like" from 11 Strategies
Nicholas Vardy

Online social media giant Facebook (FB) is a recurring favorite among Alpha Algorithm strategies, explains Nicholas Vardy, edit...

Tickers: FB
9 Reasons to Buy Texas Instruments
Nicholas Vardy

Our lasted featured recommendation is a tech name with a storied past - Texas Instruments (TXN), notes Nicholas Vardy, editor o...

Tickers: TXN
Coresite: Data and Dividends
Nicholas Vardy

Our latest recommendation takes you into the world of REITs, even as a former real estate salesman took the helm of the United...

Tickers: COR
UnitedHealth: 11 Reasons to Buy
Nicholas Vardy

Our newest recommendation offers consumer-oriented health benefit plans and services for a wide range of customers, explains Ni...

Tickers: MANH
A Trio of Top Small Cap ETFs
Nicholas Vardy

U.S. small-cap stocks are one of my favorite places to invest. That's why I have invested 100% of my son's 529 college fund in...

Tickers: RZV | PXSV | SMDV
Healthcare Services: "An Unsexy Business"
Nicholas Vardy

With the anti-health care stock scare is now fully out of the market; as a result, this healthcare company - a previous recomme...

Tickers: HCSG